查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1862225

臨床試驗：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Clinical Trial - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球臨床試驗市場預計在 2024 年達到 551.75 億美元，預計到 2031 年將達到 987.69 億美元，2025 年至 2031 年的複合年成長率為 8.8%。

臨床試驗是一種系統性的研究方法，它遵循嚴格的科學設計和倫理標準，旨在評估新藥、醫療設備、生物製藥或診斷方法的安全性、有效性和臨床適用性。臨床試驗通常分為四個階段，從I期到IV期，涵蓋從早期探索性研究到大規模驗證性研究以及上市後真實世界資料收集等一系列階段。臨床試驗在推動藥物創新、醫療設備研發和精準醫療的普及應用方面發揮關鍵作用。隨著全球醫療技術的演進和疾病模式的改變，臨床試驗正從傳統的集中式模式轉向分散式、數位化和以患者為中心的模式。在全球多中心網路、先進的試驗管理系統和嚴格的法規結構的支持下，臨床試驗能夠幫助生命科學公司加速產品商業化進程。這些既是醫療創新生態系統的科學基礎，也是其競爭優勢。

臨床試驗產業的驅動力來自對創新藥物和先進醫療設備不斷成長的投資，以及疾病模式變化帶來的日益成長的未滿足醫療需求。精準醫療、免疫療法以及細胞和基因療法的突破正在變革試驗的設計和執行方式，從而加快藥物研發週期。有利的法規結構和國際標準的日益統一提高了進行多中心和全球性試驗的可行性。人工智慧、數位平台和真實世界數據在臨床研究中的整合，正在推動效率、智慧化和全球化的提升，為投資者和產業相關人員提供了前所未有的機會。

該行業面臨的主要挑戰包括不斷上漲的試驗成本、嚴格的合規要求以及患者招募困難。監管機構對資料完整性、病人安全和倫理監督制定了嚴格的標準，導致試驗週期延長，資源投入增加。各國在政策、基礎設施和物流方面的差異也增加了全球試驗管理的複雜性。創新藥物領域日益激烈的競爭迫使企業最佳化研發資源配置，提高試驗執行效率。如何在科學嚴謹性和滿足快速的試驗週期之間取得平衡仍然是一項重大挑戰。

隨著全球醫療保健市場的演變，臨床試驗的需求日益多元化和專業化。精準醫療和伴隨診斷的進步正將試驗的重點從大規模檢驗轉向個人化研究。受託研究機構（CRO）和研究機構正在轉型為提供計劃設計、病患管理和數據分析等全方位服務供應商。遠端醫療和數位化試驗平台的興起，拓展了病患參與的機會，提高了病患參與度，並改善了數據品質。整個產業正在向以患者為中心的創新模式轉型。

上游環節包括臨床實驗藥物、對照藥物、醫療設備、診斷工具和試驗管理系統。大型製藥和醫療設備製造商正透過技術創新推動調查方法和營運效率的提升。電子健康記錄 (EHR)、電子資料收集 (EDC) 和進階分析平台的應用提高了資料的可追溯性和標準化程度。此外，供應鏈最佳化和監管協調促進了臨床實驗藥物和器械的跨境分銷，從而加強了臨床試驗的全球擴張。

本報告旨在對全球臨床試驗市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名，並按地區/國家、類型和應用對臨床試驗進行分析。

本報告以銷售收入為基準年（2024 年），對臨床試驗市場規模、估算和預測進行了呈現，並包含了 2020 年至 2031 年的歷史數據和預測數據。報告運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析公司在當前市場中的地位，並就臨床試驗做出明智的商業決策。

市場區隔

公司

  • Thermo Fisher Scientific
  • Myoderm
  • Bilcare
  • CliniChain
  • Ancillare
  • MESM
  • ERG Holding
  • Apex Medical Research
  • Parexel
  • PRA Health
  • LabCorp
  • Marken
  • AmerisourceBergen（World Courier）

按類型分類的細分市場

  • 設備（產品）
  • 消耗品
  • 其他

應用領域

  • 採購和供應
  • 租賃
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Clinical Trial was estimated to be worth US$ 55175 million in 2024 and is forecast to a readjusted size of US$ 98769 million by 2031 with a CAGR of 8.8% during the forecast period 2025-2031.

Clinical trial refers to a systematic research process conducted under rigorous scientific design and ethical standards to evaluate the safety, efficacy, and clinical applicability of new drugs, medical devices, biologics, or diagnostic methods. Typically divided into four phases (I-IV), clinical trials span early-stage exploratory research, large-scale confirmatory studies, and post-marketing real-world evidence collection, playing a critical role in advancing pharmaceutical innovation, medical device development, and precision medicine adoption. With the evolution of global healthcare technologies and changing disease patterns, clinical trials are shifting from traditional centralized models to decentralized, digitalized, and patient-centric designs. Supported by global multi-center networks, advanced trial management systems, and stringent regulatory frameworks, clinical trials enable life sciences companies to accelerate product commercialization. They represent both the scientific foundation and competitive strength of the healthcare innovation ecosystem.

The clinical trial industry is fueled by increasing investment in innovative pharmaceuticals and advanced medical devices, alongside growing unmet medical needs driven by evolving disease patterns. Breakthroughs in precision medicine, immunotherapies, and cell and gene therapies are transforming trial design and execution, enabling faster drug development cycles. Favorable regulatory frameworks and growing international harmonization of standards have improved the feasibility of multi-center, global trials. The integration of AI, digital platforms, and real-world data into clinical research is driving greater efficiency, intelligence, and globalization, presenting unprecedented opportunities for investors and industry players.

Key industry challenges include rising trial costs, stringent compliance requirements, and difficulties in patient recruitment. Regulatory agencies impose strict standards for data integrity, patient safety, and ethical oversight, leading to longer timelines and increased resource commitments. Variability in policies, infrastructure, and logistics between countries adds complexity to global trial management. With heightened competition in the innovative drug sector, companies face greater pressure to optimize R&D resource allocation and trial execution efficiency. Balancing scientific rigor with accelerated timelines remains a major hurdle.

Demand for clinical trials is becoming increasingly diverse and specialized as global healthcare markets advance. Precision medicine and companion diagnostics are shifting trial focus from large-scale validation to individualized studies. CROs and research institutions are evolving into full-service providers, offering project design, patient management, and data analytics. The rise of telemedicine and digital trial platforms is broadening patient participation, improving engagement, and enhancing data quality. The industry is moving toward a more patient-centric innovation model.

The upstream segment includes investigational drugs, comparators, medical devices, diagnostic tools, and trial management systems. Leading pharmaceutical and device manufacturers are driving innovation in trial methodologies and operational efficiency through technological advancements. Adoption of electronic health records (EHRs), electronic data capture (EDC), and advanced analytics platforms has improved data traceability and standardization. Additionally, supply chain optimization and regulatory harmonization are facilitating cross-border distribution of trial drugs and equipment, reinforcing the global expansion of clinical trials.

This report aims to provide a comprehensive presentation of the global market for Clinical Trial, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Clinical Trial by region & country, by Type, and by Application.

The Clinical Trial market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Trial.

Market Segmentation

By Company

  • Thermo Fisher Scientific
  • Myoderm
  • Bilcare
  • CliniChain
  • Ancillare
  • MESM
  • ERG Holding
  • Apex Medical Research
  • Parexel
  • PRA Health
  • LabCorp
  • Marken
  • AmerisourceBergen (World Courier)

Segment by Type

  • Instruments (Products)
  • Consumables
  • Others

Segment by Application

  • Procurement and Supplies
  • Rentals
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Clinical Trial company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Clinical Trial in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Clinical Trial in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Clinical Trial Product Introduction
  • 1.2 Global Clinical Trial Market Size Forecast (2020-2031)
  • 1.3 Clinical Trial Market Trends & Drivers
    • 1.3.1 Clinical Trial Industry Trends
    • 1.3.2 Clinical Trial Market Drivers & Opportunity
    • 1.3.3 Clinical Trial Market Challenges
    • 1.3.4 Clinical Trial Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Clinical Trial Players Revenue Ranking (2024)
  • 2.2 Global Clinical Trial Revenue by Company (2020-2025)
  • 2.3 Key Companies Clinical Trial Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Clinical Trial Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Clinical Trial
  • 2.6 Clinical Trial Market Competitive Analysis
    • 2.6.1 Clinical Trial Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Clinical Trial Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Trial as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Instruments (Products)
    • 3.1.2 Consumables
    • 3.1.3 Others
  • 3.2 Global Clinical Trial Sales Value by Type
    • 3.2.1 Global Clinical Trial Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Clinical Trial Sales Value, by Type (2020-2031)
    • 3.2.3 Global Clinical Trial Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Procurement and Supplies
    • 4.1.2 Rentals
    • 4.1.3 Others
  • 4.2 Global Clinical Trial Sales Value by Application
    • 4.2.1 Global Clinical Trial Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Clinical Trial Sales Value, by Application (2020-2031)
    • 4.2.3 Global Clinical Trial Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Clinical Trial Sales Value by Region
    • 5.1.1 Global Clinical Trial Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Clinical Trial Sales Value by Region (2020-2025)
    • 5.1.3 Global Clinical Trial Sales Value by Region (2026-2031)
    • 5.1.4 Global Clinical Trial Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Clinical Trial Sales Value, 2020-2031
    • 5.2.2 North America Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Clinical Trial Sales Value, 2020-2031
    • 5.3.2 Europe Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Clinical Trial Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Clinical Trial Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Clinical Trial Sales Value, 2020-2031
    • 5.5.2 South America Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Clinical Trial Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Clinical Trial Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Clinical Trial Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Clinical Trial Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Clinical Trial Sales Value, 2020-2031
    • 6.3.2 United States Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Clinical Trial Sales Value, 2020-2031
    • 6.4.2 Europe Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Clinical Trial Sales Value, 2020-2031
    • 6.5.2 China Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Clinical Trial Sales Value, 2020-2031
    • 6.6.2 Japan Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Clinical Trial Sales Value, 2020-2031
    • 6.7.2 South Korea Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Clinical Trial Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Clinical Trial Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Clinical Trial Sales Value, 2020-2031
    • 6.9.2 India Clinical Trial Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Clinical Trial Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher Scientific
    • 7.1.1 Thermo Fisher Scientific Profile
    • 7.1.2 Thermo Fisher Scientific Main Business
    • 7.1.3 Thermo Fisher Scientific Clinical Trial Products, Services and Solutions
    • 7.1.4 Thermo Fisher Scientific Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Thermo Fisher Scientific Recent Developments
  • 7.2 Myoderm
    • 7.2.1 Myoderm Profile
    • 7.2.2 Myoderm Main Business
    • 7.2.3 Myoderm Clinical Trial Products, Services and Solutions
    • 7.2.4 Myoderm Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Myoderm Recent Developments
  • 7.3 Bilcare
    • 7.3.1 Bilcare Profile
    • 7.3.2 Bilcare Main Business
    • 7.3.3 Bilcare Clinical Trial Products, Services and Solutions
    • 7.3.4 Bilcare Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Bilcare Recent Developments
  • 7.4 CliniChain
    • 7.4.1 CliniChain Profile
    • 7.4.2 CliniChain Main Business
    • 7.4.3 CliniChain Clinical Trial Products, Services and Solutions
    • 7.4.4 CliniChain Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.4.5 CliniChain Recent Developments
  • 7.5 Ancillare
    • 7.5.1 Ancillare Profile
    • 7.5.2 Ancillare Main Business
    • 7.5.3 Ancillare Clinical Trial Products, Services and Solutions
    • 7.5.4 Ancillare Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Ancillare Recent Developments
  • 7.6 MESM
    • 7.6.1 MESM Profile
    • 7.6.2 MESM Main Business
    • 7.6.3 MESM Clinical Trial Products, Services and Solutions
    • 7.6.4 MESM Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.6.5 MESM Recent Developments
  • 7.7 ERG Holding
    • 7.7.1 ERG Holding Profile
    • 7.7.2 ERG Holding Main Business
    • 7.7.3 ERG Holding Clinical Trial Products, Services and Solutions
    • 7.7.4 ERG Holding Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.7.5 ERG Holding Recent Developments
  • 7.8 Apex Medical Research
    • 7.8.1 Apex Medical Research Profile
    • 7.8.2 Apex Medical Research Main Business
    • 7.8.3 Apex Medical Research Clinical Trial Products, Services and Solutions
    • 7.8.4 Apex Medical Research Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Apex Medical Research Recent Developments
  • 7.9 Parexel
    • 7.9.1 Parexel Profile
    • 7.9.2 Parexel Main Business
    • 7.9.3 Parexel Clinical Trial Products, Services and Solutions
    • 7.9.4 Parexel Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Parexel Recent Developments
  • 7.10 PRA Health
    • 7.10.1 PRA Health Profile
    • 7.10.2 PRA Health Main Business
    • 7.10.3 PRA Health Clinical Trial Products, Services and Solutions
    • 7.10.4 PRA Health Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.10.5 PRA Health Recent Developments
  • 7.11 LabCorp
    • 7.11.1 LabCorp Profile
    • 7.11.2 LabCorp Main Business
    • 7.11.3 LabCorp Clinical Trial Products, Services and Solutions
    • 7.11.4 LabCorp Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.11.5 LabCorp Recent Developments
  • 7.12 Marken
    • 7.12.1 Marken Profile
    • 7.12.2 Marken Main Business
    • 7.12.3 Marken Clinical Trial Products, Services and Solutions
    • 7.12.4 Marken Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Marken Recent Developments
  • 7.13 AmerisourceBergen (World Courier)
    • 7.13.1 AmerisourceBergen (World Courier) Profile
    • 7.13.2 AmerisourceBergen (World Courier) Main Business
    • 7.13.3 AmerisourceBergen (World Courier) Clinical Trial Products, Services and Solutions
    • 7.13.4 AmerisourceBergen (World Courier) Clinical Trial Revenue (US$ Million) & (2020-2025)
    • 7.13.5 AmerisourceBergen (World Courier) Recent Developments

8 Industry Chain Analysis

  • 8.1 Clinical Trial Industrial Chain
  • 8.2 Clinical Trial Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Clinical Trial Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Clinical Trial Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Clinical Trial Market Trends
  • Table 2. Clinical Trial Market Drivers & Opportunity
  • Table 3. Clinical Trial Market Challenges
  • Table 4. Clinical Trial Market Restraints
  • Table 5. Global Clinical Trial Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Clinical Trial Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Clinical Trial Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Clinical Trial Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Clinical Trial
  • Table 10. Global Clinical Trial Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Trial as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Clinical Trial Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Clinical Trial Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Clinical Trial Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Clinical Trial Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Clinical Trial Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Clinical Trial Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Clinical Trial Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Clinical Trial Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Clinical Trial Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Clinical Trial Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Clinical Trial Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Clinical Trial Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Clinical Trial Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Clinical Trial Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Clinical Trial Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Clinical Trial Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Clinical Trial Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Clinical Trial Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Thermo Fisher Scientific Basic Information List
  • Table 32. Thermo Fisher Scientific Description and Business Overview
  • Table 33. Thermo Fisher Scientific Clinical Trial Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Clinical Trial Business of Thermo Fisher Scientific (2020-2025)
  • Table 35. Thermo Fisher Scientific Recent Developments
  • Table 36. Myoderm Basic Information List
  • Table 37. Myoderm Description and Business Overview
  • Table 38. Myoderm Clinical Trial Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Clinical Trial Business of Myoderm (2020-2025)
  • Table 40. Myoderm Recent Developments
  • Table 41. Bilcare Basic Information List
  • Table 42. Bilcare Description and Business Overview
  • Table 43. Bilcare Clinical Trial Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Clinical Trial Business of Bilcare (2020-2025)
  • Table 45. Bilcare Recent Developments
  • Table 46. CliniChain Basic Information List
  • Table 47. CliniChain Description and Business Overview
  • Table 48. CliniChain Clinical Trial Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Clinical Trial Business of CliniChain (2020-2025)
  • Table 50. CliniChain Recent Developments
  • Table 51. Ancillare Basic Information List
  • Table 52. Ancillare Description and Business Overview
  • Table 53. Ancillare Clinical Trial Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Clinical Trial Business of Ancillare (2020-2025)
  • Table 55. Ancillare Recent Developments
  • Table 56. MESM Basic Information List
  • Table 57. MESM Description and Business Overview
  • Table 58. MESM Clinical Trial Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Clinical Trial Business of MESM (2020-2025)
  • Table 60. MESM Recent Developments
  • Table 61. ERG Holding Basic Information List
  • Table 62. ERG Holding Description and Business Overview
  • Table 63. ERG Holding Clinical Trial Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Clinical Trial Business of ERG Holding (2020-2025)
  • Table 65. ERG Holding Recent Developments
  • Table 66. Apex Medical Research Basic Information List
  • Table 67. Apex Medical Research Description and Business Overview
  • Table 68. Apex Medical Research Clinical Trial Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Clinical Trial Business of Apex Medical Research (2020-2025)
  • Table 70. Apex Medical Research Recent Developments
  • Table 71. Parexel Basic Information List
  • Table 72. Parexel Description and Business Overview
  • Table 73. Parexel Clinical Trial Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Clinical Trial Business of Parexel (2020-2025)
  • Table 75. Parexel Recent Developments
  • Table 76. PRA Health Basic Information List
  • Table 77. PRA Health Description and Business Overview
  • Table 78. PRA Health Clinical Trial Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Clinical Trial Business of PRA Health (2020-2025)
  • Table 80. PRA Health Recent Developments
  • Table 81. LabCorp Basic Information List
  • Table 82. LabCorp Description and Business Overview
  • Table 83. LabCorp Clinical Trial Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Clinical Trial Business of LabCorp (2020-2025)
  • Table 85. LabCorp Recent Developments
  • Table 86. Marken Basic Information List
  • Table 87. Marken Description and Business Overview
  • Table 88. Marken Clinical Trial Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Clinical Trial Business of Marken (2020-2025)
  • Table 90. Marken Recent Developments
  • Table 91. AmerisourceBergen (World Courier) Basic Information List
  • Table 92. AmerisourceBergen (World Courier) Description and Business Overview
  • Table 93. AmerisourceBergen (World Courier) Clinical Trial Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Clinical Trial Business of AmerisourceBergen (World Courier) (2020-2025)
  • Table 95. AmerisourceBergen (World Courier) Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Clinical Trial Downstream Customers
  • Table 99. Clinical Trial Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Clinical Trial Product Picture
  • Figure 2. Global Clinical Trial Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Clinical Trial Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Clinical Trial Report Years Considered
  • Figure 5. Global Clinical Trial Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Clinical Trial Revenue in 2024
  • Figure 7. Clinical Trial Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Instruments (Products) Picture
  • Figure 9. Consumables Picture
  • Figure 10. Others Picture
  • Figure 11. Global Clinical Trial Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Clinical Trial Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Procurement and Supplies
  • Figure 14. Product Picture of Rentals
  • Figure 15. Product Picture of Others
  • Figure 16. Global Clinical Trial Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Clinical Trial Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Clinical Trial Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Clinical Trial Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Clinical Trial Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Clinical Trial Sales Value (%), (2020-2031)
  • Figure 29. United States Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Clinical Trial Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Clinical Trial Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Clinical Trial Industrial Chain
  • Figure 51. Clinical Trial Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed